Abeona Therapeutics Adds Keith Goldan to Board, Audit Chair

The latest update is out from Abeona Therapeutics ( (ABEO) ).

On April 7, 2026, Abeona Therapeutics announced that Keith A. Goldan had been appointed as an independent member of its Board of Directors, effective April 1, 2026, and as Chairman of the Audit Committee. With more than two decades of financial leadership across commercial-stage biotechnology and specialty pharmaceutical companies, Goldan’s appointment underscores Abeona’s intent to reinforce its strategic and financial oversight as it scales as a commercial-stage biotech.

Goldan’s background includes CFO roles at Syndax Pharmaceuticals, Optinose, Fibrocell, NuPathe, PuriCore and Biosyn, along with earlier leadership positions at ViroPharma and KPMG, where he led core finance and corporate functions and executed multiple capital markets and M&A transactions. His addition to Abeona’s board is expected to support the company’s first U.S. commercial launch, ongoing capital markets activities and broader growth plans, with the board emphasizing his role in driving value for both patients and shareholders.

The most recent analyst rating on (ABEO) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Abeona Therapeutics stock, see the ABEO Stock Forecast page.

Spark’s Take on ABEO Stock

According to Spark, TipRanks’ AI Analyst, ABEO is a Neutral.

The score is held down primarily by weak underlying financial performance (large operating losses and ongoing cash burn despite a stronger 2025 balance sheet) and soft technical momentum. Offsetting these is a more positive earnings-call outlook driven by reimbursement milestones (permanent J-code, broad payer coverage) and early commercialization ramp plans, though execution and adoption pace remain key risks.

To see Spark’s full report on ABEO stock, click here.

More about Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for serious diseases. Its lead product, ZEVASKYN (prademagene zamikeracel), is the first and only autologous cell-based gene therapy approved for treating wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa, supported by an in-house cGMP manufacturing facility in Cleveland, Ohio.

The company also maintains a development portfolio of adeno-associated virus-based gene therapies targeting ophthalmic diseases with high unmet medical need. Abeona is advancing next-generation AAV capsids to address a range of devastating conditions, positioning itself within the rare disease and ophthalmology segments of the biotechnology market.

On April 7, 2026, Abeona Therapeutics announced that Keith A. Goldan had been appointed as an independent member of its Board of Directors, effective April 1, 2026, and as Chairman of the Audit Committee. With more than two decades of financial leadership across commercial-stage biotechnology and specialty pharmaceutical companies, Goldan’s appointment underscores Abeona’s intent to reinforce its strategic and financial oversight as it scales as a commercial-stage biotech.

Goldan’s background includes CFO roles at Syndax Pharmaceuticals, Optinose, Fibrocell, NuPathe, PuriCore and Biosyn, along with earlier leadership positions at ViroPharma and KPMG, where he led core finance and corporate functions and executed multiple capital markets and M&A transactions. His addition to Abeona’s board is expected to support the company’s first U.S. commercial launch, ongoing capital markets activities and broader growth plans, with the board emphasizing his role in driving value for both patients and shareholders.

Average Trading Volume: 1,249,663

Technical Sentiment Signal: Strong Sell

Current Market Cap: $271.6M

For a thorough assessment of ABEO stock, go to TipRanks’ Stock Analysis page.